Insight Holdings Group, LLC and its affiliated investment funds have executed a substantial divestment of Hinge Health, Inc. Class A Common Stock, reporting the sale of 1,466,667 shares for a total value of approximately $121.5 million on June 29, 2026. The transactions were carried out under the framework of a Rule 10b5-1 trading plan, which was originally adopted on August 20, 2025. The shares were sold at weighted average prices that ranged from $81.305 to $84.59 per share.
Prior to these sales, on June 25, 2026, Insight Holdings Group and its affiliates converted 1,466,667 shares of Class B Common Stock into Class A Common Stock. Each share of Class B Common Stock is convertible into one share of Class A Common Stock. Insight Holdings Group, LLC, along with its various investment partnerships including Insight Venture Partners X, L.P., Insight Venture Partners (Cayman) X, L.P., Insight Venture Partners (Delaware) X, L.P., and Insight Venture Partners X (Co-Investors), L.P., are designated as ten percent owners of Hinge Health. The shares are held indirectly through a structure involving general partners and managing entities.
According to InvestingPro analysis, HNGE appears overvalued at current levels based on its Fair Value assessment. Investors seeking deeper insights can access a comprehensive Pro Research Report, available for HNGE and 1,400+ other US stocks.
In other recent news, Hinge Health has garnered attention from multiple analyst firms following its Investor Day at the Movement client conference. Canaccord raised its price target for the company to $76, emphasizing Hinge Health’s growth outlook, particularly its expectation to add 4 to 5 million covered lives during the 2026 selling season. KeyBanc also increased its price target to $90, highlighting new product offerings, including a surgical expansion through HingeSelect. Citizens maintained its Market Outperform rating with an $80 price target, reaffirming confidence after attending the company’s conference.
Hinge Health FollowAnalyze HNGEIncluded in our AI-picked strategies·Review strategies81.48▲+2.51(+3.18%)Closed·15:59:59·USD82.00▲+0.52(+0.64%)After Hours·19:50:121D1W1M6M1Y5YMaxCreated with Highcharts 11.4.814:0015:0016:0017:0018:0019:0078808284Analyze HNGETruist Securities raised its price target to $85, citing a strong belief in the company’s positioning for its next growth phase. Stifel reiterated a Buy rating and a $79 price target, focusing on the surgical option addition and revised financial targets discussed during the investor session. These developments underscore a positive sentiment from analysts regarding Hinge Health’s strategic initiatives and growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.See the trade on HNGE, but can't pull the trigger?Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.Try Chart Analysis for HNGE